A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants

In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin.
In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI):
Both devices are designed to deliver litifilimab in an automatic way, especially helping patients who may not be able to use their hands very well, or who may be afraid of needles. While the AI is handheld, the OBI device works by being placed on the skin and can help deliver the highest amount of litifilimab through a single injection. The main objective of this study is to learn how the body processes litifilimab after using the AI device or the OBI device, as compared to using the PFS method.
The main questions researchers want to answer are:
* What is the highest amount of litifilimab found in the blood after dosing? How much total litifilimab is found in the blood throughout the study? Researchers will also learn more about: Any medical problems the participants have during the study
* Any injection site pain or reactions the participants may have. Any skin reactions to the OBI device
* Any changes in the participants' overall health after receiving litifilimab.
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks, after which selected participants will check into their study research center.
* Participants will be randomly assigned to be in Part 1 or Part 2 of the study:
* Part 1: Participants will receive SC injection(s) of litifilimab through either the AI device or through PFS.
* Part 2: Participants will receive SC injection(s) of litifilimab through the OBI device or through PFS.
* Participants will remain at their study research center for the first 8 days. After that, there will be a follow-up period for 17 weeks during which participants return to the center a total of 6 times.
Each participant will be in the study for about 22 weeks.

Start Date02 Jan 2025

Sponsor / Collaborator

Biogen, Inc.

CTR20234203

/ RecruitingPhase 3

一项在患有活动性亚急性皮肤型红斑狼疮和/或慢性皮肤型红斑狼疮（有或无全身表现）且抗疟药治疗反应不佳和/或不耐受的受试者中评价 BIIB059 疗效和安全性的 2 部分无缝设计（A 部分 [II 期]/B 部分 [III 期]）、随机、双盲、安慰剂对照、多中心临床研究 (AMETHYST)

[Translation] A 2-part seamless design (Part A [Phase II]/Part B [Phase III]), randomized, double-blind, placebo-controlled, multicenter clinical study (AMETHYST) to evaluate the efficacy and safety of BIIB059 in subjects with active subacute cutaneous lupus erythematosus and/or chronic cutaneous lupus erythematosus (with or without systemic manifestations) who have an inadequate response and/or intolerance to antimalarial therapy

本研究的总体目的是在患有活动性 SCLE 和/或 CCLE（有或无全身表现）且抗疟药治疗反应不佳和/或不耐受的受试者中评价 BIIB059 与安慰剂相比的疗效和安全性。

[Translation]

The overall objective of this study was to evaluate the efficacy and safety of BIIB059 compared with placebo in subjects with active SCLE and/or CCLE (with or without systemic manifestations) who had an inadequate response to and/or intolerance to antimalarial therapy.

Start Date26 Jun 2024

Sponsor / Collaborator

Biogen Idec Research Ltd.

[+2]

NCT06044337

/ Enrolling by invitationPhase 3

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
The study will enroll only those participants who have completed treatment with litifilimab in the parent study, 230LE301.
The main objective of the study is to learn more about the long-term safety of litifilimab.
The main question researchers want to answer is:
- How many participants have adverse events and serious adverse events after taking litifilimab? Adverse events are unwanted health problems that may or may not be caused by the study drug.
Researchers will also learn more about the effect of litifilimab on CLE. They will do this by measuring the symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
Researchers will look at how litifilimab and CLE affect the quality of life of participants using a group of questionnaires. They will also look at how litifilimab affects laboratory tests and how participants' immune systems respond to litifilimab.
The study will be done as follows:
* The last visit of parent study 230LE301 will be the first visit of study 230LE305.
* All participants will receive litifilimab as an injection under the skin once every 4 weeks. Both researchers and participants will know the dose and identity of the study drug.
* Globally, the treatment period will last up to 104 weeks, or 2 years. For participants in the United States, the treatment period may last up to 260 weeks, or 5 years
* There will be a follow-up safety period that lasts up to 24 weeks.
* Globally, participants will have up to 27 study visits during the treatment period. In the US, participants will have up to 66 study visits.
* Globally, the total study duration for participants will be up to 128 weeks. In the US, the total study duration will be up to 284 weeks .

Start Date03 Oct 2023

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Litifilimab

100 Translational Medicine associated with Litifilimab

100 Patents (Medical) associated with Litifilimab

Literatures (Medical) associated with Litifilimab

01 Jul 2025·CPT-Pharmacometrics & Systems Pharmacology

An Integrative Mechanistic Model of Type 1 IFN‐Mediated Inflammation in Systemic Lupus Erythematosus

Article

Author: Volkova, Alina ; Tettamanti, Florencia ; Ugolkov, Yaroslav ; Kimko, Holly ; Sokolov, Victor ; Tang, Weifeng ; Peskov, Kirill ; Verma, Meghna

ABSTRACT:

Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).

04 Mar 2025·EXPERT OPINION ON INVESTIGATIONAL DRUGS

A focused report on IFN-1 targeted therapies for lupus erythematosus

Review

Author: Furie, Richard ; Vashistha, Himanshu ; Bhatt, Anushka ; Gupta, Pramiti

INTRODUCTION:

Patients with Systemic Lupus Erythematosus (SLE) experience varied manifestations and unpredictable flares, complicating treatment and drug development. Despite these challenges, anifrolumab, voclosporin, and belimumab were approved by FDA. These treatments complement, but don't replace, traditional therapies like NSAIDs, corticosteroids, antimalarials, and immunosuppressives. Therefore, there remains an unmet need for more effective medications targeting excessive proinflammatory cytokines in SLE patients.

AREAS COVERED:

This review summarizes the clinical trial outcomes of four upcoming medications targeting cytokine activity: Litifilimab showed a 7-point reduction in CLASI-A in its phase II trial. Daxdilimab was unsuccessful in its phase II trial. Anifrolumab reduced SLE activity in both phase II and III trials. Deucravacitinib decreased disease activity by multiple measures in its phase II trial.

EXPERT OPINION:

High levels of IFN-I (type 1 interferon) are present in most SLE patients, making this pathway an attractive target for drug development. Litifilimab downregulates IFN-I by targeting BDCA2, while dexadilimab targets ILT7 to recruit effector cells, reducing IFN-I production by killing PDCs. Anifrolumab binds to the IFN-I receptor, blocking the activity of all IFN-Is, and deucravacitinib reduces IFN-I by inhibiting TYK2, thereby interfering with downstream signaling. Therapies that target IFN-I represents a promising class of medications for SLE patients.

11 Feb 2025·Immunotherapy

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary

Article

Author: Meyers, Adam ; Carroll, Hua ; Musselli, Cristina ; Furie, Richard A ; Franchimont, Nathalie ; Romero-Diaz, Juanita ; Navarra, Sandra ; Kalunian, Kenneth ; van Vollenhoven, Ronald F ; Werth, Victoria ; Huang, Xiaobi ; Barbey, Catherine

What is this summary about?The LILAC study was performed in two separate parts, to see how litifilimab, an antibody, worked for two distinct forms of lupus. In Part A, summarized in this manuscript, litifilimab was evaluated in participants diagnosed with systemic lupus erythematosus (SLE) with active joint and skin disease. In Part B, litifilimab was administered to participants with moderate-to-severe cutaneous lupus erythematosus (CLE) with or without SLE. This is a summary of the main results from Part A, which were published in the New England Journal of Medicine in 2022. Part A of the LILAC study analyzed the treatment effects of litifilimab compared with placebo, a nonactive control treatment that looks like and is taken the same way as the study drug. Side effects (undesirable secondary effects) were monitored to evaluate the safety of the treatment.What were the results?A total of 120 participants received litifilimab or placebo. The primary measure (main objective) was assessed at Week 24 of the study. A 28-joint clinical assessment (28 specified joints) was used to measure the specific treatment effects on the joints, and the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI–A) scale was used to assess its effects on the skin. The SLE Responder Index (SRI)–4 combined score was used to measure SLE disease activity across the entire body.The results demonstrated that, on average, participants who received litifilimab had a lower total number of swollen and tender joints after 24 weeks than those who received placebo. Also, compared with participants who received placebo, more participants who received litifilimab had a reduction of at least 7 points in their CLASI-A score, meaning their skin disease reduced, and had reductions in SRI-4 responses, meaning their SLE disease activity was reduced across multiple organ systems. The side effects observed (e.g., diarrhea, the common cold, urinary tract infections, falls and headaches) were mostly mild or moderate in severity, without any major differences between the groups.What do the results of the study mean?SLE has no cure and, although there are medications used to manage symptoms, new treatments are needed. The results summarized here show that litifilimab may be a treatment option for patients with SLE that affects their joints and skin. Larger studies are continuing to evaluate litifilimab in patients with SLE.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text

News (Medical) associated with Litifilimab

04 Dec 2025

·www.fiercebiotech.com

Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision

Royalty Pharma penned similar financing deals this year with Biogen, Zenas BioPharma and Revolution Medicines.\n While Denali Therapeutics awaits a delayed FDA decision on its Hunter syndrome drug, the biotech is already banking on the therapy’s commercial success.The agency had originally been due to make an approval call for the enzyme replacement therapy, called tividenofusp alfa, in early January 2026. But the FDA recently pushed back the decision date by three months.While Denali waits for the regulator’s verdict in April, the biotech is busy leveraging the potential sales tividenofusp alfa could bring in. This morning’s deal with Royalty Pharma, a buyer of biopharmaceutical royalties, will give Denali access to $200 million if the drug secures FDA approval, with an additional $75 million to follow if the therapy gets the green light in Europe.In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times the amount if the target is achieved by the first quarter of 2039.“We are delighted to partner with Denali and acquire a royalty on tividenofusp alfa, an innovative therapy that addresses a significant unmet need in the cognitive and physical manifestations of Hunter syndrome,” Royalty’s CEO and founder Pablo Legorreta said in the release.“Denali’s technology platform delivers therapeutics across the blood-brain barrier and is a promising new approach to brain diseases,” Legorreta added. “We are thrilled to establish a relationship with Denali and believe tividenofusp alfa is a potential practice-changing therapy that could transform the lives of patients with Hunter syndrome.” Royalty has penned similar financing deals so far this year, helping Biogen bankroll phase 3 development of its lupus candidate litifilimab, allowing Zenas BioPharma to complete work on its autoimmune candidate obexelimab and supporting Revolution Medicines in commercializing its lung cancer drug daraxonrasib.Denali already had almost $873 million in the bank at the end of September. CEO Ryan Watts, Ph.D., said the additional funds from Royalty would ensure the biotech was “well positioned to advance our development programs as we prepare for the launch of tividenofusp alfa, unlocking broad opportunities across serious diseases.”Tividenofusp alfa is a version of the iduronate 2-sulfatase enzyme that is engineered to penetrate the blood-brain barrier by binding to transferrin receptor 1, which normally shuttles iron into the brain.When Denali revealed the three-month delay to the FDA’s decision date back in October, the company put the move in the context of the updated clinical pharmacology information it had supplied to the FDA as part of the application review process. While Denali said this information was not related to the drug’s efficacy, safety or biomarkers, and did not involve supplying any additional clinical data, the FDA classified the submission as a major amendment to the application, which requires a three-month extension to the deadline.Hunter syndrome, also called mucopolysaccharidosis type II (MPS II), is characterized by patients\' inability to break down certain sugars, which leads to tissue and organ damage that ultimately causes stiff joints, delayed growth and enlarged spleens and livers, among other symptoms. The disease can also lead to cognitive and behavioral problems, and, in severe cases, patients may not survive beyond their teenage years.There is one approved enzyme replacement therapy for Hunter syndrome in Takeda’s Elaprase, which the Japanese drugmaker secured as part of its acquisition of Shire Pharmaceuticals in 2019.In August, the FDA pushed back the approval decision deadline for another Hunter syndrome treatment in the form of Regenxbio’s gene therapy clemidsogene lanparvovec after requesting additional data.

AcquisitionPhase 3

24 Oct 2025

·www.fiercebiotech.com

Biogen beefs up immunology pipeline with $1B deal for Vanqua\'s preclinical C5aR1 antagonist

Biogen’s current immunology pipeline is led by dapirolizumab pegol, a UCB-partnered anti-CD40L drug that notched a phase 3 win in systemic lupus erythematosus last year.\n Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.Biogen described C5aR1 as a “well-validated target involved in neutrophil-mediated inflammation.” The biopharma is banking on applying the oral C5aR1 antagonist’s mechanism across “multiple immune-mediated diseases” with an ambition of entering the clinic in 2027.C5aR1 plays an important role in the immune cascade that causes tissue inflammation, particularly in neutrophil-mediated conditions. There’s an obvious overlap with Biogen’s own izastobart, an antibody directed against C5aR1 the company has been evaluating in a phase 1 study.Beyond the $70 million upfront payment from this morning’s deal, Chicago-based Vanqua is in line for up to $990 million in potential development, regulatory, commercial and sales milestone payments as well as tiered royalties should a drug make it to market.“This agreement reflects our strong commitment to building a comprehensive immunology pipeline with a strategic focus on both innate and adaptive immune pathways,” Biogen\'s head of research Jane Grogan, Ph.D., said in this morning’s release.“C5aR1 is a well-validated target involved in neutrophil-mediated inflammation, which plays a central role across a range of inflammatory disorders,” Grogan added. “Advancing this program enables us to deepen our scientific and clinical focus in immunological diseases where we believe Biogen can make a meaningful difference for patients.” Biogen’s current immunology pipeline is led by dapirolizumab pegol, a UCB-partnered anti-CD40L drug that notched a phase 3 win in systemic lupus erythematosus last year. Also in late-stage development for lupus is the anti-BDCA2 antibody litifilimab, along with felzartamab, a monoclonal antibody designed to deplete CD38+ plasma cells, which is being evaluated for antibody-mediated rejection and various types of nephropathy.Both felzartamab and the phase 1-stage izastobart were acquired as part of Biogen’s buyout of Human Immunology Biosciences (HI-Bio) last year.“Biogen’s scale, development rigor, and global commercialization capabilities make them uniquely positioned to advance this compound for patients with inflammatory disorders,” Vanqua CEO Jim Sullivan, Ph.D., said in today\'s release.“The discovery of a highly differentiated C5aR1 inhibitor validates the small molecule drug discovery capabilities of the Vanqua team,” Sullivan added. “Furthermore, this transaction allows Vanqua to remain focused on our CNS pipeline while ensuring that this program can be developed to its full potential.”William Blair analysts said the deal with Vanqua “adds an intriguing, albeit early, preclinical-stage asset to Biogen’s growing immunology pipeline aligned with its therapeutic pipeline strategy.” “We continue to see developing excitement about Biogen’s late-stage neurology and immunology pipeline, which may provide a longer-term solution to the eroding MS franchise and slower-than-anticipated Leqembi launch,” the analysts added in an Oct. 24 note.The deal follows Biogen’s reorganization at the beginning of the year that included layoffs and a shift to focus on external opportunities. Shortly after announcing the restructure, Biogen paid Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet syndrome.Since then, the company has abandoned work on adeno-associated virus gene therapies while penning a big biobucks deal with RNAi-focused City Therapeutics and buying drug delivery specialist Alcyone Therapeutics.

$Biogen beefs up immunology pipeline with $1B deal for Vanqua\'s preclinical C5aR1 antagonist$

ImmunotherapyPhase 1Phase 3Acquisition

24 Oct 2025

·firstwordpharma.com

Biogen buys into Vanqua's preclinical C5aR1 asset for up to $1.1B

Biogen inked a deal worth up to $1.1 billion with Vanqua Bio, securing exclusive global rights to a preclinical oral C5aR1 antagonist, the companies announced Friday. The agreement adds another inflammation-focused asset to Biogen's growing immunology portfolio.C5aR1 plays a key role in driving critical components of the immune cascade involved in tissue inflammation, particularly in neutrophil-mediated conditions. In preclinical testing, the compound blocked complement activation of pathogenic immune cells and showed a safety profile supportive of clinical advancement, according to the companies."C5aR1 is a well-validated target involved in neutrophil-mediated inflammation, which plays a central role across a range of inflammatory disorders," said Jane Grogan, Biogen's head of research. "This agreement reflects our strong commitment to building a comprehensive immunology pipeline with a strategic focus on both innate and adaptive immune pathways."IND planned for 2027Under the deal, Biogen will pay Vanqua $70 million upfront and up to $990 million in potential milestones, along with tiered royalties on future sales. Biogen will assume responsibility for all future development, manufacturing and commercialisation efforts, and said it expects to file an IND application in 2027 if preclinical results continue to support the programme.The deal is in line with Biogen's shift in research strategy, confirmed early this year, that includes a newly prioritised preclinical portfolio and a focus on external collaborations. Some transactions over the last year and half include its $1.15-billion acquisition of Human Immunology Biosciences (HI-Bio) and collaboration on RNAi therapies with City Therapeutics potentially worth over $1 billion.Biogen's immunology pipeline now includes six Phase III programmes; namely, dapirolizumab pegol and litifilimab for lupus, and felzartamab, acquired through the HI-Bio deal, for nephropathy and antibody-mediated rejection.

ImmunotherapyAcquisitionPhase 3License out/inClinical Result

100 Deals associated with Litifilimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lupus Erythematosus, Cutaneous	Phase 3	United States	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	China	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Japan	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Argentina	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Belgium	Biogen Idec Research Ltd.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Brazil	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Bulgaria	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Canada	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Chile	Biogen, Inc.	03 Oct 2023
Lupus Erythematosus, Cutaneous	Phase 3	Colombia	Biogen, Inc.	03 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02847598 (LILAC \| LILAC study, CTgov)	Phase 2	Lupus Erythematosus, Cutaneous \| Systemic Lupus Erythematosus \| Lupus Erythematosus, Discoid	264	Placebo (Part A: Placebo)	amxgpziexz(orslztyrvs) = mnbxoyncdn subxulhyal (agodukmmnq, 10.3) View more	-	15 May 2023
				BIIB059 (litifilimab) (Part A: BIIB059 450 mg)	amxgpziexz(orslztyrvs) = baipuhalvr subxulhyal (agodukmmnq, 8.7) View more
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	Phase 2	Systemic Lupus Erythematosus BDCA2	132	Litifilimab 450 mg	eljygraoel(hwsbymmjum): P-Value = 0.04 View more	Positive	08 Sep 2022
				Placebo
NCT02847598 (LILAC, Pubmed \| N Engl J Med)	Phase 2	Lupus Erythematosus, Cutaneous	132	Litifilimab 50 mg	mafctbctjh(cgtwvhpius) = Litifilimab was associated with one case of herpes zoster infection grxfpmfuiu (ukwmuyizfb ) View more	Positive	28 Jul 2022
				Litifilimab 150 mg
NCT02847598 (LILAC study, EULAR2022)	Phase 2	Lupus Erythematosus, Cutaneous BDCA2	-	BIIB059	xrxfrslmuk(jvkkzkldcn) = dgqlqvmqvg jtsbqraxdu (azytdtryrf ) View more	Positive	01 Jun 2022
NCT02847598 (LILAC, EULAR2022)	Phase 2	Systemic Lupus Erythematosus anti-nuclear antibodies \| anti-double-stranded DNA antibodies	-	BIIB059 450 mg	dhhbujivsf(btkdlytnkr) = kpupaplgas dnmtecicso (tiusgpdjdo ) View more	Positive	01 Jun 2022
				Placebo	dhhbujivsf(btkdlytnkr) = okyykzlvuv dnmtecicso (tiusgpdjdo ) View more
NCT02847598 (LILAC, ACR2020) Manual	Phase 2	Systemic Lupus Erythematosus	120	BIIB059	bkhgymamjz(jqlfpiufuk) = xokwzbfdrx xpxidwgqxx (prqvzfnykm, 1.2) View more	Positive	07 Nov 2020
				Placebo	bkhgymamjz(jqlfpiufuk) = wzujzopzsb xpxidwgqxx (prqvzfnykm, 1.3) View more
NCT02847598 (LILAC, EULAR2020)	Phase 2	Lupus Erythematosus, Cutaneous	132	BIIB059 50 mg	xgpeglninj(tcepbrizxv) = 62 (62.6%) 80 (60.6%) rcirawmiwy (tcavhbsopb ) View more	Positive	03 Jun 2020
				BIIB059 150 mg
NCT02847598 (Pubmed \| J Pharmacokinet Pharmacodyn)	Phase 2	Lupus Erythematosus, Cutaneous	264	BIIB059	rhapatoden(neurgyynvb) = gaaiieambh pphxagriyq (uspohapkeq ) View more	-	01 Jun 2020
NCT02106897 (Pubmed \| J Clin Invest) Manual	Phase 1	Eczema \| Systemic Lupus Erythematosus	54	BIIB059	ansqjklhct(wqqmgsfkzt) = xgrvffjxjx uqlubjsolt (lfrvvbhpia ) View more	Positive	01 Mar 2019
				Placebo	ansqjklhct(wqqmgsfkzt) = brcrkjiind uqlubjsolt (lfrvvbhpia ) View more
NCT02106897 (EULAR2018)	Phase 1	BDCA2 on pDC	-	BIIB059 20 mg/kg IV	tntdyaiugh(mopiulzcbs) = lpyxgfscqz mwemnbrmxq (eoyarjctel ) View more	-	13 Jun 2018
				BIIB059 20, 50 or 150 mg SC	xaekghasig(frfxmbrvdr) = uhfzqitxam thdrdvtrdv (vbmlevugfa ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis